

- 25) A Multicenter Study of Recombinant Factor VIII (Recombinate) in Previously Treated Patients with Hemophilia A. White II G. C., et al., *Thromb Haemost.* 77:660-667, 1997
- 26) Sucrose Formulated Recombinant Human Antihemophilic Factor VIII is Safe and Efficacious for Treatment of Hemophilia A in Home Therapy. Abshire T.C., et al., *Thromb Haemost.* 83:811-6, 2000
- 27) Lack of Evidence for Increased Inhibitor Incidence in Patients Swerched from Plasma-derived to Recombinant Factor VIII. Scharrer I., *Haemophilia* 7:346-348, 2001
- 28) 過去に治療歴のある血友病 A 患者に対する遺伝子組換え型血液凝固第Ⅷ因子製剤（リコネイト）の市販後の多施設臨床評価（使用成績調査） 福武勝幸 他 *日本血栓止血学会雑誌* 16 : 650—663、2005
- 29) Inhibitor in congenital coagulation disorders. Key N.S., *Br. J. Haematol.* 127:379-91, 2004
- 30) Factor VIII Inhibitors Ed. Hoyer L.W. ALAN R. LISS. New York 1984
- 31) The incidence of factor VIII and factor IX inhibitors in the hemophilia population of UK and their effect on subsequent mortality, 1977-99. UKHCDO、*J Thrombosis and Haemostasis* 2:1047-54, 2004
- 32) Inhibitor to Factor VIII- mild and moderate hemophilia. Peerlinck K., *Textbook of Hemophilia* Lee C.A. 71-73, 2005
- 33) Increased frequency of inhibitor in African American Hemophilia A patients. Addiego JE et al., *Blood Supple* 1:239a, 1994
- 34) Why do inhibitors develop ? Principles of and factors influencing the risk for inhibitor development in haemophilia ? Astermark J., *Haemophilia* 12 *Suppl.3* 52-60, 2006
- 35) Inhibitors to factor VIII-molecure baias. Oldenburg J., *Textbook of Hemophilia* Lee C.A. 59-63, 2005
- 36) REPORT OF EXPERT MEETING ON FACTOR VIII PRODUCTS AND INHIBITOR DEVELOPMENT London, 22 February 2007 EMEA
- 37) Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Van den Bom et. al., *Thrombosis and Haemostasis* 89:475-9, 2003
- 38) Incidence of factor VIII inhibitors in severe haemophilia the importance of patient age. Lorenzo JI et al., *Br. J. Haematol* 113:600-3, 2001
- 39) Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A. Sharathkumar A., wt al., *J of Thrombosis and Haemostasis* 1: 1228-1236, 2003
- 40) Prpphyllactic treatment effects on inhibitor risk:experience in one centre. Morado M., et al., *Haemophilia* 11:79-83, 2005
- 41) Environmental risk factor for inhibitor development in children with haemophilia A: a case-control study. *British J of Haematology* 130:422-427, 2005